Clinical TrialJun 30, 2026, 04:07 PM
4D Molecular Therapeutics to Present 4D-150 Phase 2b Data at ASRS
AI Summary
4D Molecular Therapeutics announced it will present 2-year follow-up data from its PRISM Phase 2b clinical trial for investigational 4D-150 at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS). The presentation, focusing on a broad neovascular AMD population, is scheduled for July 18, 2026, and will be delivered by Carl Awh, MD, FASRS.
Key Highlights
- 4D Molecular Therapeutics to present 2-year follow-up data for 4D-150.
- Data from the PRISM Phase 2b clinical trial for neovascular AMD.
- Presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).
- Presentation scheduled for Saturday, July 18, 2026, from 2:58 – 3:01 p.m. ET.
- Presenter will be Carl Awh, MD, FASRS, from Tennessee Retina.
- 4D-150 is an investigational intravitreal gene therapy for broad neovascular AMD population.
Price Impact
More from FDMT